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Abstract 
A phase III clinical trial showed gemcitabine chemotherapy combined with epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib significantly improved 
overall  survival  in  patients  with  advanced  pancreatic  cancer.  Therefore,  we  studied 
whether addition of gemcitabine to erlotinib in cancer cells having intrinsic or acquired 
erlotinib resistance could restore chemosensitization in these cells. We studied the syn-
ergistic effect of erlotinib and gemcitabine in EGFR-overexpressing A-431 cells with ac-
quired erlotinib resistance and in intrinsic erlotinib-resistant triple negative breast cancer 
(TNBC) BT-549, MDA-MB-231 and MDA-MB-468 cell lines. Erlotinib and gemcitabine 
were synergistic in both parental intrinsically erlotinib-sensitive A-431 cells (combination 
index = 0.69 at the effective dose [ED50]) and in two A-431 cell pools that had acquired 
erlotinib resistance (combination indices = 0.63 and 0.49 at ED50). The synergistic effect of 
erlotinib and gemcitabine on cancer cells did not require sensitivity to erlotinib provided 
that erlotinib can inhibit EGFR. The restoration of sensitivity by gemcitabine occurred 
through  downregulation  of  phosphorylated  Akt  (p-Akt),  which  suggests  that 
PI3K-PTEN-Akt activity is important to the synergism between the two agents. In A-431 
parental cells, treatment with gemcitabine followed by erlotinib – but not the reverse 
sequence – was superior to erlotinib alone. The importance of the order of administration 
maybe  due  to  the  downregulation  of  p-Akt  by  gemcitabine  in  a  dose-  and 
time-dependent manner in cells with intrinsic or acquired erlotinib resistance. Our data 
show  that  gemcitabine  increased  the  cytotoxic  effect  of  erlotinib  by  downregulating 
p-Akt in EGFR-overexpressing cells with either intrinsic or acquired erlotinib resistance. 
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Introduction 
Epidermal  growth  factor  receptor  (EGFR),  a 
member  of  the  ErbB  family  of  receptor  tyrosine  ki-
nases,  is  overexpressed  in  many  solid  malignancies 
and is associated with poor clinical prognosis. As a 
result, EGFR is considered to be an attractive target 
for  cancer  treatment1,2.  Two  pharmacologic  ap-
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proaches  one  with  monoclonal  antibodies  and  the 
other with EGFR tyrosine kinase inhibitors targeting 
EGFR have been successfully developed3.  
Erlotinib is a small molecule EGFR inhibitor that 
targets EGFR’s adenosine triphosphate (ATP)-binding 
sites, resulting in the inhibition of EGFR tyrosine ki-
nase activity. Erlotinib was the first anti-EGFR agent 
to be used to extend the survival of patients with ad-
vanced non–small cell lung cancer4 and currently is 
being investigated as a therapy for several types of 
tumors in multiple clinical trials3,5. Erlotinib was re-
cently approved by the United States Food and Drug 
Administration for combination use with gemcitabine 
in the treatment of advanced pancreatic cancer3,5. Er-
lotinib  offers  clinical  benefit  to  a  subset  of  patients 
with  non–small  cell  lung  cancer.  However,  most  of 
these patients demonstrate disease progression within 
1 year, and whether erlotinib should be included in a 
combination chemotherapeutic regimen at that point 
has been unclear. 
However, resistance to EGFR tyrosine kinase in-
hibitors  presents  a  therapeutic  challenge;  some  tu-
mors  seem  to  resist  these  drugs  intrinsically,  and 
cancers  that  initially  respond  frequently  acquire  re-
sistance6,7,8.  The  phosphatidylinositol  3-kinase 
(PI3K)-PTEN-Akt pathway is thought to be involved 
in intrinsic mechanisms of resistance to EGFR inhibi-
tors,  including  erlotinib9,10,11,12,  and  we  have  previ-
ously shown that it is involved in acquired resistance 
to erlotinib8. Therefore, it is possible that targeting the 
PI3K-PTEN-Akt  pathway  in  combination  with  erlo-
tinib  treatment  would  enhance  cytotoxicity  and  in-
crease the efficacy of erlotinib and other EGFR inhib-
itors. Intrinsic and acquired erlotinib resistances are 
associated with upregulation of Akt activity. Target-
ing  PI3K-PTEN-Akt  specifically  offers  a  theoretical 
advantage because it is the convergence point for a 
number of upstream signaling pathways; thus, mul-
tiple  pathways  could  be  blocked  by  inhibition  of 
PI3K-PTEN-Akt  alone.  However,  no  therapeutically 
useful  direct  PI3K-PTEN-Akt  inhibitors  have  been 
identified  to  date.  Because  gemcitabine  is  the  only 
drug that is recognized to have a combination effect 
with  erlotinib,  we  decided  to  investigate  whether 
gemcitabine  targets  the  PI3K-PTEN-Akt  pathway 
when combined with erlotinib.  
 With this background in mind, the purpose of 
this  study  was  to  assess  the  role  of  PI3K-PEN-Akt 
inhibition in gemcitabine’ s ability to reverse erlotinib 
resistance. We designed a study to determine whether 
the addition of gemcitabine to erlotinib in cancer cells 
having intrinsic or acquired erlotinib resistance could 
restore  chemosensitization  in  these  cells,  and  if  so, 
whether the PI3K-PTEN-Akt pathway was involved. 
Herein,  we  report  that  when  gemcitabine  was  fol-
lowed  by  erlotinib  treatment,  it  synergistically  de-
creased the viability of cancer cells by restoring sensi-
tivity  to  erlotinib.  The  restoration  of  sensitivity  by 
gemcitabine  occurred  through  downregulation  of 
p-Akt, which suggests that PI3K-PTEN-Akt activity is 
involved  in  the  synergistically  increased  apoptosis 
and  is  an  important  mechanism  for  understanding 
and overcoming erlotinib resistance.  
Materials and Methods 
 Chemotherapeutic agents and cell lines.  Erlo-
tinib  was  dissolved  in  dimethyl  sulfoxide  at  5 
mmol/L  as  described  previously13.  Clinical-grade 
gemcitabine (Eli Lilly and Co, Indianapolis, IN) was 
purchased and dissolved in sterile water at 100 mM. 
 For studies of cells with acquired resistance to 
erlotinib,  we  previously  established  A-431  epider-
moid  cancer  cells8  that  overexpress  EGFR  and  are 
sensitive to erlotinib. We developed two pools of er-
lotinib-resistant A-431 cells by continuously exposing 
them to erlotinib (10 mol/L for pool 1 and 5 mol/L 
for pool 2) for 6 months as described previously8. The 
cells regained morphologic characteristics similar to 
those of the parental line after 6 months of erlotinib 
exposure.  Erlotinib  resistance  was  confirmed  as  de-
scribed  previously8.  The  resistant  cells  were  main-
tained in medium without erlotinib for at least 1 week 
before each experiment was performed.  
For  studies  of  cells  with  intrinsic  resistance  to 
erlotinib,  we  also  obtained  triple-negative  BT-549, 
MDA-MB-231,  and  MDA-MB-468  cells  from  the 
American  Type  Culture  Collection  (Manassas,  VA). 
These  are  EGFR-overexpressing  breast  cancer  cell 
lines that are intrinsically resistant to erlotinib13. 
 Dose-response studies. A-431 parental cells and 
samples from both pools of A-431 cells with acquired 
erlotinib resistance were seeded at 500 cells/well in 
96-well dishes. After 24 h, the cells were treated in 
quadruplicate for 72 h with 2-fold serial dilutions of 
erlotinib  alone,  gemcitabine  alone,  or  both  drugs 
simultaneously at a fixed ratio of 2 M erlotinib:7 nM 
gemcitabine. After 72 h, a 3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium  bromide  (MTT)  assay  was 
performed as described previously13. All experiments 
were performed at least three times. Growth inhibi-
tion  was  expressed  as  the  percentage  of  remaining 
viable cells relative to the number of viable cells in 
untreated cultures, which was set at 100%. Combina-
tion indices (CIs) were obtained using the commercial 
software  package  CalcuSyn  (Biosoft,  Cambridge, 
UK)14.  Drug  synergism,  addition,  and  antagonism 
were defined by CI values of <1.0, 1.0, and >1.0, re-
spectively. For each drug, at least three doses above  Journal of Cancer 2011, 2 
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and three doses below the individual effective dose 
(ED50) were tested to determine the median effect as 
calculated by the computer software. 
 The  dose-response  study  was  also  performed 
with BT-549, MDA-MB-231, and MDA-MB-468 breast 
cancer cells to assess the combination effect of erlo-
tinib and gemcitabine on intrinsic erlotinib resistance. 
The procedure was exactly the same except that the 
ratio was 2 M erlotinib: 10 nM gemcitabine. 
Time course studies. We tried three time courses 
to investigate the combination effect of erlotinib and 
gemcitabine. In the first schedule, erlotinib and gem-
citabine  were  given  simultaneously.  In  the  second 
schedule, the cells were treated with gemcitabine for 
72 h and then with erlotinib for another 72 h. In the 
third schedule, the cells were treated with erlotinib for 
72 h and then with gemcitabine for another 72 h.  
 Trypan blue exclusion assay. In order to assess 
cell viability and thereby gauge the efficacy of com-
bination  therapy  on  each  of  the  types  of  cells,  we 
performed a trypan blue exclusion assay as described 
previously8. Briefly, A-431 parental cells and samples 
from both pools of erlotinib-resistant cells were plated 
and treated with 2 M erlotinib, 7 nM gemcitabine, or 
both  drugs  simultaneously.  After  72  h  of  exposure, 
floating  and  adhering  cells  were  collected  by  tryp-
sinization and counted under a microscope.   
Cell cycle analysis. As a measure of apoptosis, 
cell-cycle  analysis  was  performed  to  determine  the 
percentage of cells in the sub-G1 phase of the cell cy-
cle,  as  described  in  our  previous  report13.  Briefly, 
A-431 parental cells and samples from both pools of 
erlotinib-resistant cells were treated with 2 M erlo-
tinib,  7  nM  gemcitabine,  or  both  drugs  simultane-
ously.  After  72  h  of  drug  treatment,  the  cells  were 
fixed overnight in 70% ethanol and then resuspended 
in  propidium  iodide.  DNA  content  was  measured 
using  a  FACScan  cytometer  (Becton  Dickinson, 
Franklin Lakes, NJ). 
Western  blotting.  Western  blotting  was  per-
formed  as  described  previously13.  Immunoblotting 
and  immunoprecipitation  were  performed  with  the 
following  antibodies:  mouse  anti-EGFR  (Ab-12;  Lab 
Vision,  Fremont,  CA);  mouse  anti–p-Akt  (Ser  473, 
#4051)  and  rabbit  anti-Akt  (#9272;  both  from  Cell 
Signaling Technology, Beverly, MA); and mouse an-
ti–-actin  (A-5441; Sigma  Chemical,  St.  Louis,  MO). 
Signals were detected using an Odyssey infrared im-
aging system (LI-COR Biosciences, Lincoln, NE). 
Results 
Synergistic effect of erlotinib and gemcitabine in 
cell lines with acquired erlotinib resistance  
The EGFR-overexpressing A-431 cells (parental 
erlotinib-sensitive  cells  and  two  pools  of  erlo-
tinib-resistant cells) were treated with serial dilutions 
of  erlotinib,  gemcitabine,  or  both  drugs  simultane-
ously at a fixed ratio spanning the ED50 of each drug. 
Table 1 shows the affected fraction of cells versus the 
CI  (synergistic)  values  for  the  drug  mixture  for  all 
three cell lines. 
In the A-431 parental cells, the drug combination 
resulted in a CI value of 0.69 at ED50, indicating syn-
ergism  between  erlotinib  and  gemcitabine.  In  both 
erlotinib-resistant pools of cells, the drug combination 
resulted in CI values very similar to that of the pa-
rental cells (with CI values of 0.63 for pool 1 and 0.49 
for  pool  2).  The  sensitivities  of  both  pools  of  erlo-
tinib-resistant cells to gemcitabine were very similar 
(ED50 pool 1, 11.8 nM; ED50 pool 2, 10.3 nM). There-
fore,  erlotinib  was  shown  to  enhance  the  cytotoxic 
effects of gemcitabine in EGFR-overexpressing cancer 
cells even after acquired erlotinib-resistance.  
 
Table 1 Synergistic Effect of Erlotinib and Gemcitabine 
in Cell Lines with Acquired Erlotinib Resistance 
  A-431  Combination Indices     
  Cell Line  ED50  ED75  ED90  Dm 
Mixture  Parental  0.69257  0.70776   0.72472   0.83689 
  Pool 1  0.62572  0.68561   0.76407   1.89010 
   Pool 2  0.49079  0.49590   0.51086   1.20910 
Erlotinib  Parental         1.76766 
(µM)  Pool 1        28.8355 
   Pool 2           15.4557 
Gemcitabine  Parental        13.3674 
(nM)  Pool 1        11.8092 
   Pool 2           10.2576 
Dm means the median effect dose, it is analogous to the IC50) 
 
Increase in apoptosis after erlotinib and gem-
citabine treatment 
We performed flow-cytometric cell-cycle analy-
sis  to  determine  whether  the  results  of  the 
dose-response  assays  were  a  reflection  of  cell-cycle 
arrest or apoptosis. Similar to other DNA-damaging 
agents, gemcitabine promotes apoptosis15,16, and we 
expected gemcitabine treatment to induce apoptosis 
in our A-431 cells. Indeed, the percentage of parental 
cells treated with 7 nM gemcitabine that were in the 
sub-diploid (sub-G1) phase was 5 times higher than 
the  percentage  of  untreated  parental  cells  in  the 
sub-diploid phase (Fig. 1). This percentage increased 
to a further 3 to 4 times higher in parental cells treated 
with both 2 M erlotinib and 7 nM gemcitabine. Both 
erlotinib-  resistant  cell  pools  demonstrated  similar  Journal of Cancer 2011, 2 
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synergistic increases in apoptosis after treatment with 
gemcitabine and erlotinib (Fig. 1).  
 
 
Fig. 1. Erlotinib and gemcitabine synergistically increased 
their rate of apoptosis in EGFR-overexpressing A-431 epi-
dermoid cancer cells with intrinsic (parental) or acquired 
(pools 1 and 2) erlotinib resistance. Cells were treated with 
2 µM erlotinib, 7 nM gemcitabine, or both simultaneously. 
After 72 h of drug treatment, the cells were fixed, resus-
pended in propidium iodide, and analyzed for DNA content 
using  a  FACScan  cytometer.  The  extent  of  changes  in 
sub-diploid  content  (sub-G1 cell-cycle  phase)  relative  to 
untreated  cells  was  assessed  to  determine  the  levels  of 
apoptosis.  
 
Optimal timing of gemcitabine and erlotinib 
treatment  
We next examined whether the order in which 
gemcitabine  and  erlotinib  were  administered  influ-
enced cell survival in erlotinib-resistant cells. We first 
examined the level of cytotoxicity in response to three 
different  schedules  of  gemcitabine  and  erlotinib.  In 
the  first  schedule,  erlotinib  and  gemcitabine  were 
given  simultaneously,  which  resulted  in  the  en-
hancement  of  erlotinib-mediated  cytotoxicity  by 
gemcitabine (see Fig. 1). In the second schedule, A-431 
parental cells were treated with gemcitabine for 72 h 
and then with erlotinib for another 72 h, and a similar 
synergistic effect was observed (Fig. 2A). In contrast to 
the first and second schedules, when the cells were 
treated with erlotinib first and then gemcitabine, there 
was no additive effect (Fig. 2B).  
 
Downregulation of p-Akt expression by gemcita-
bine  
Since resistance to erlotinib is known to be asso-
ciated with increased levels of p-Akt, a prosurvival 
molecule  downstream  of  EGFR,  we  examined 
whether  treatment  of  cells  with  gemcitabine  would 
decrease the expression level of p-Akt and whether 
gemcitabine  could  overcome  erlotinib  resistance  by 
inhibiting Akt activity. In previous studies, we have 
shown that by treating cells with an Akt inhibitor IV, 
erlotinib sensitivity was restored in erlotinib-resistant 
pools of A-431 cells8. Accordingly, we investigated the 
p-Akt expression level in A-431 cells after treatment 
with gemcitabine. As expected, the level of p-Akt was 
decreased after treatment with gemcitabine at doses 
of 3.5–14 nM in both erlotinib-sensitive parental cells 
and erlotinib-resistant cells (Fig. 3) and in the TNBC 
cell  lines  BT-549  and  MDA-MB-468  after  treatment 
with gemcitabine at a dose of 100nM (Fig. 4).  
 
 
 
Fig. 2. Effect of erlotinib and gemcitabine treatment schedule on parental A-431 cells. A. Cells were treated with 0 or 3.5 
nM gemcitabine for 72 h and then with 0.125–16 M erlotinib for 72 h. A synergistic effect was observed. B. In contrast, a 
synergistic effect was not observed when cells were treated with 0 or 10 M erlotinib for 72 h and then with 0.4375–56 nM 
gemcitabine for 72 h. Note that the concentration along the x-axis scale in each graph doubles at each tick mark.  Journal of Cancer 2011, 2 
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Fig. 3. Protein expression levels of Akt and p-Akt were analyzed by Western blotting after treatment with gemcitabine in 
both  erlotinib-sensitive  A-431  cells  (parental)  and  erlotinib-resistant  A-431  cells  (two  pools).  p-Akt  but  not  Akt  was 
downregulated in both erlotinib-sensitive and erlotinib-resistant cells. -actin was used as a loading control.  
 
 
Fig. 4. Protein expression levels of Akt and p-Akt were analyzed by Western blotting after treatment with gemcitabine in 
erlotinib-resistant BT-549 and MDA-MB-468 breast cancer cells. p-Akt but not Akt was downregulated in both cell lines. 
-actin was used as a loading control. 
 
Synergistic effect of erlotinib and gemcitabine in 
breast cancer cell lines with intrinsic erlotinib 
resistance 
Finally, we examined the combined effect of er-
lotinib and gemcitabine in breast cancer cell lines in-
trinsically resistant to erlotinib. We used TNBC cell 
lines  BT-549,  MDA-MB-468,  and  MDA-MB-231  be-
cause these cell lines express EGFR and high levels of 
unphosphorylated Akt and are intrinsically resistant 
to erlotinib. The cells  were treated with  serial dilu-
tions of erlotinib, gemcitabine, or both drugs simul-
taneously at a fixed ratio spanning the ED50 of each 
drug. The measurements of cell viability at the vari-
ous  drug  concentrations  are  shown  in  Table  2.  In 
BT-549, MDA-MB-468, and MDA-MB-231 cells at the  Journal of Cancer 2011, 2 
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ED50, the drug combination resulted in CI values of 
0.39, 0.82, and 0.71, respectively, indicating synergism 
between these two agents. The sensitivity levels (in 
terms of ED50) of these cells to gemcitabine alone were 
342 nM in BT-549 cells, 29.2 nM in MDA-MB-468 cells, 
and  10.3  nM  in  MDA-MB-231  cells.  These  results 
suggest that a synergistic effect of erlotinib and gem-
citabine was also seen in breast cancer lines with in-
trinsic  erlotinib  resistance  EGFR-overexpressing 
TNBC.  
Similar  to  as  was  seen  in  A-431  cells, 
MDA-MB-468 breast cancer cells treated with 8 nM 
gemcitabine had similar percentages of cells that were 
in  the  sub-G1phase  as  did  untreated  cells,  whereas 
this percentage increased to 1.9 times that of untreat-
ed  cells  and  1.7  times  that  of  just  erlotinib  in 
MDA-MB-468 cells administered both 2 M erlotinib 
and 8 nM gemcitabine (data not shown). 
 
Table 2. Synergistic Effect of Erlotinib and Gemcitabine 
in Cell Lines with Intrinsic Erlotinib Resistance 
    Combination Indices   
   Cell Line  ED50  ED75  ED90  Dm 
Mixture  BT-549  0.39275  0.26629  0.18403   6.89283 
  MDA-MB-468  0.81612  0.70875  0.65044   2.88089 
   MDA-MB-231  0.70510  0.55634  0.45635   2.42506 
Erlotinib  BT-549         23.59856 
(µM)  MDA-MB-468         8.90787 
   MDA-MB-231            25.7763 
Gemcitabine  BT-549        342.3832 
(nM)  MDA-MB-468         29.2352 
   MDA-MB-231            10.3228 
 
 
Discussion 
In  this  study,  we  showed  that  gemcitabine  in-
creases the cytotoxic effect of erlotinib via downreg-
ulation of p-Akt. This synergistic effect, in the form of 
enhanced apoptosis, was observed both in cells with 
intrinsic erlotinib resistance and cells with acquired 
erlotinib resistance8. 
Through these findings, we have shown that the 
restoration  of  sensitivity  by  gemcitabine  occurred 
through  downregulation  of  p-Akt,  which  suggests 
that PI3K-PTEN-Akt activity is critical to the syner-
gistic effect of the two drugs on cell death    
Our findings are consistent with those of other 
groups suggesting that erlotinib given first, followed 
by gemcitabine, had no effect, whereas gemcitabine 
followed  by  erlotinib  produced  a  synergistic  effect. 
Our previous studies revealed that erlotinib can target 
EGFR  in  cells  with  either  intrinsic  erlotinib  re-
sistance13 or acquired erlotinib resistance8 by inhibit-
ing  the  phosphorylation  of  EGFR.  Another  study 
demonstrated that erlotinib significantly inhibited the 
phosphorylation of EGFR and other downstream ki-
nases  and  significantly  promoted  gemcita-
bine-induced apoptosis in vivo17. Our in vitro model of 
EGFR-driving  cancer  cells  now  indicates  that  the 
growth-inhibitory  effects  in  such  cells  of  erlotinib 
combined  with  gemcitabine  could  apply  even  after 
the cells have acquired erlotinib resistance. The mo-
lecular  mechanisms  behind  the  synergism  between 
erlotinib  and  gemcitabine  most  likely  involved  the 
decreased p-Akt expression caused by gemcitabine. In 
addition, other investigators have also shown that the 
administration  of  gemcitabine  first  followed  by  ge-
fitinib increased the therapeutic index of such therapy 
over that of gemcitabine alone18, and cytotoxic syner-
gism  was  also  found  to  result  when  cells  were  ex-
posed to concurrent pemetrexed and erlotinib or se-
quential  pemetrexed  followed  by  erlotinib  in  both 
erlotinib-sensitive  and  erlotinib-resistant  human 
non–small  cell  lung  cancer  cell  lines.  These  studies 
support  the  importance  of  drug  scheduling  in  the 
treatment of cancer7. The latter regimen may be more 
effective because treatment with erlotinib causes G1 
cell-cycle arrest8, thereby reducing the cytotoxic effect 
of gemcitabine, as gemcitabine mainly affects cells in 
the S phase of the cell cycle. 
To clarify the mechanisms behind the synergism 
between  gemcitabine  and  erlotinib,  other  investiga-
tors  have  shown  that  gemcitabine  increases  EGFR 
-phosphorylation and subsequently induces the EGFR 
degradation that may be  a mechanism for gemcita-
bine-mediated cell death19. This is an interesting ob-
servation because the degradation of EGFR may result 
in downregulation of p-Akt in some cell lines, leading 
to apoptosis,  which is consistent  with our findings. 
Also,  genistein  (a  naturally  occurring  isoflavone  in 
soybeans) has been reported to increase the cytotoxic 
effect induced by erlotinib in certain pancreatic cancer 
cells through the inhibition of Akt and nuclear fac-
tor–B20.  That  study  and  our  results  suggest  that 
downstream  molecules  of  the  Akt  pathway  are  in-
volved in the synergistic effect of erlotinib and gem-
citabine.  
We  have  shown  that  one  of  the  molecular 
mechanisms involved in the development of acquired 
erlotinib resistance is p-Akt upregulation subsequent 
to  PTEN  downregulation8.  Multiple  molecular 
mechanisms  of  resistance  to  EGFR  tyrosine  kinase 
inhibitors exist; they include mutations in the EGFR 
tyrosine kinase domain, modification of other path-
ways, such as those of HER3, IGF-R, and E-cadherin8, 
hepatocyte growth factor, and amplification of MET  Journal of Cancer 2011, 2 
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proto-oncogenes21. These mechanisms may vary from 
one  tumor  or  patient  to  the  next.  Therefore,  even 
though  we  observed  an  enhanced  response  to  erlo-
tinib  after  treating  our  erlotinib-resistant  cell  pools 
with gemcitabine, other erlotinib-resistant cell pools 
derived from other EGFR-overexpressing lines might 
not yield the same results. Hence, further elucidating 
the mechanisms by which these cancers develop erlo-
tinib  resistance  is  imperative.  Another  possibility  is 
that  temporarily  interrupting  erlotinib  therapy  and 
administering non-erlotinib chemotherapy to patients 
with  erlotinib-resistant  cancers  could  eventually  re-
store cell sensitivity to erlotinib. In a previous in vitro 
study,  a  6-month  interruption  of  a  continuous 
maintenance regimen of gefitinib did restore cell sen-
sitivity to gefitinib21. 
Our results showed that gemcitabine increased 
the  cytotoxic  effect  of  erlotinib  by  downregulating 
p-Akt  in  EGFR-overexpressing  cells  with  either  in-
trinsic or acquired erlotinib resistance. These findings 
indicate that further studies are needed to understand 
the molecular mechanisms by which gemcitabine acts 
synergistically with erlotinib. We can speculate that 
the continued treatment of erlotinib-resistant cancers 
with a combination of erlotinib and gemcitabine may 
be effective. The enhanced understanding of the mo-
lecular mechanism behind these agents elucidated by 
our  findings  may  help  to  develop  more  effective 
therapeutic  targets  for  enhancing  the  synergism  of 
other agents with erlotinib.  
Acknowledgments 
This work was supported by the Nellie B. Con-
nally  Breast  Cancer  Research  Fund;  National  Insti-
tutes of Health R01 grant CA123318-01A1 (NU); Japan 
Society for the Promotion of Science Grant-in-Aid for 
Scientific Research and grants-in-aid from the Japan 
Society  for  the  Promotion  of  Science  grant  No. 
22591612 (FY); and National Cancer Institute Cancer 
Center Support Grant CA-16672 (support of the Flow 
Cytometry and Cellular Imaging Core Facility and the 
Media Preparation Core Facility at The University of 
Texas MD Anderson Cancer Center). We thank Sunita 
Patterson,  Maude  Veech,  and  Elizabeth  L.  Hess, 
ELS(D), Department of Scientific Publications at MD 
Anderson  Cancer  Center,  for  their  expert  editorial 
review. 
Conflict of Interest 
The authors have declared that no conflict of in-
terest exists. 
References 
[1]  Ciardiello F, Tortora G. A novel approach in the treatment of 
cancer:  targeting  the  epidermal  growth  factor  receptor.  Clin 
Cancer Res. 2001; 7: 2958-70. 
[2]  Ono  M,  Kuwano  M.  Molecular  mechanisms  of  epidermal 
growth factor receptor (EGFR) activation and response to ge-
fitinib and other EGFR-targeting drugs. Clin Cancer Res. 2006; 
12: 7242-51. 
[3]  Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, 
Ciardiello F. Erlotinib in cancer treatment. Ann Oncol. 2007; 18 
(Suppl 6): vi35-41. 
[4]  Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in 
previously treated non-small-cell lung cancer. N Engl J Med. 
2005; 353: 123-32. 
[5]  Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting 
of solid tumors. Cancer Control. 2007; 14: 295-304. 
[6]  Bunn PAJr. Can acquired resistance to epidermal growth factor 
receptor  tyrosine  kinase  inhibitors  be  overcome  by  different 
small-molecule tyrosine kinase inhibitors? J Clin Oncol. 2007; 
25: 2504-5. 
[7]  Tabernero J. The role of VEGF and EGFR inhibition: implica-
tions  for  combining  anti-VEGF  and  anti-EGFR  agents.  Mol 
Cancer Res. 2007; 5: 203-20. 
[8]  Yamasaki F, Johansen MJ, Zhang D, et al. Acquired resistance to 
erlotinib  in  A-431  epidermoid  cancer  cells  requires 
down-regulation  of  MMAC1/PTEN  and  up-regulation  of 
phosphorylated Akt. Cancer Res. 2007; 67: 5779-88. 
[9]  Engelman  JA,  Janne  PA,  Mermel  C,  et  al.  ErbB-3  mediates 
phosphoinositide  3-kinase  activity  in  gefitinib-sensitive 
non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 
2005; 102: 3788-93. 
[10] Maiello MR, D'Alessio A, De Luca A, et al. AZD3409 inhibits 
the growth of breast cancer cells with intrinsic resistance to the 
EGFR  tyrosine  kinase  inhibitor  gefitinib.  Breast  Cancer  Res 
Treat. 2007; 102: 275-82. 
[11] Ono  M,  Hirata  A,  Kometani  T,  et  al.  Sensitivity  to  gefitinib 
(Iressa, ZD1839) in non-small cell lung cancer cell lines corre-
lates with dependence on the epidermal growth factor (EGF) 
receptor/extracellular  signal-regulated  kinase  1/2  and  EGF 
receptor/Akt pathway for proliferation. Mol Cancer Ther. 2004; 
3: 465-72. 
[12] Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth 
factor receptor, protein kinase B/Akt, and glioma response to 
erlotinib. J Natl Cancer Inst. 2005; 97: 880-7. 
[13] Yamasaki F, Zhang D, Bartholomeusz C, et al. Sensitivity of 
breast cancer cells to   erlotinib  depends  on  cyclin-dependent 
kinase 2 activity. Mol Cancer Ther. 2007; 6:  2168-77. 
[14] Chou TC, Talalay P. Quantitative analysis of dose-effect rela-
tionships: the combined effects of multiple drugs or enzyme 
inhibitors. Adv Enzyme Regul. 1984; 22: 27-55. 
[15] Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced pro-
grammed cell death (apoptosis) of human pancreatic carcinoma 
is determined by Bcl-2 content. Ann Surg Oncol. 1999; 6: 279-85. 
[16] Cartee L, Kucera GL, Willingham MC. Induction of apoptosis 
by gemcitabine in BG-1 human ovarian cancer cells compared 
with  induction  by  staurosporine,  paclitaxel  and  cisplatin. 
Apoptosis. 1998; 3: 439-49. 
[17] Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epider-
mal  growth  factor  receptor  inhibitor  OSI-774,  Tarceva,  on 
downstream signaling pathways and apoptosis in human pan-
creatic adenocarcinoma. Mol Cancer Ther. 2002; 1: 777-83. 
[18] Chun  PY,  Feng  FY,  Scheurer  AM,  Davis  MA,  Lawrence  TS, 
Nyati MK. Synergistic effects of gemcitabine and gefitinib in the 
treatment of head and neck carcinoma. Cancer Res. 2006; 66: 
981-8.  Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
442 
[19] Feng FY, Varambally S, Tomlins SA, et al. Role of epidermal 
growth  factor  receptor  degradation  in  gemcitabine-mediated 
cytotoxicity. Oncogene. 2007; 26: 3431-9. 
[20] El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH. 
Potentiation of the effect of erlotinib by genistein in pancreatic 
cancer: the role of Akt and nuclear factor-kappaB. Cancer Res. 
2006; 66: 10553-9. 
[21] Ando K, Ohmori T, Inoue F, et al. Enhancement of sensitivity to 
tumor necrosis factor alpha in non-small cell lung cancer cells 
with acquired resistance to gefitinib. Clin Cancer Res. 2005; 11: 
8872-9.  